Central Garden & Pet Stock (NASDAQ: CENTA)

Latest news for Central Garden & Pet (NASDAQ:CENTA) Stock

Central Garden & Pet

Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.

Earnings

Mid Cap

News

Penny Stocks

Dividends

Price Target

Small Cap

Federal Reserve

Markets

Analyst Ratings

Tech

Trading Ideas

CENTA

EVLV

SBLK

In late 2023, many analysts called for 2024 to be the year of a small-cap stock renaissance. These stocks were battered as the Federal Reserve aggressively raised interest rates. Many of these companies rely on borrowing to fund their growth and struggled as the cost of borrowing increased. 

3 Small-Cap Stocks on the Way to Bigger and Better Days


In late 2023, many analysts called for 2024 to be the year of a small-cap stock renaissance. These stocks were battered as the Federal Reserve aggressively raised interest rates. Many of these companies rely on

Dati deludenti sull'occupazione USA e i mercati crollano

Pre-Market Outlook

BMBL

BOOT

EDIT

LYFT

PETQ

Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday

Central Garden & Pet Company - Class A Common Stock Nonvoting

Central Garden & Pet Co

Centamin PLC

Centaur Media PLC

CENTAURUS ENERGY INC by Centaurus Energy Inc.

Centaurus Energy Inc

CENTAURUS METALS LTD ORD by Centaurus Metals Ltd.

Centaurus Metals Ltd

JP Morgan analyst Andrea Faria maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $32 to $31.

JP Morgan Maintains Neutral on Central Garden & Pet, Lowers Price Target to $31

Argus Research analyst John Eade downgrades Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) from Buy to Hold.

Downgrades

Argus Research Downgrades Central Garden & Pet to Hold

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.02 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Central Garden & Pet Q4

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:02 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.02, resulting in a 0.0% increase change in the share price the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Central Garden & Pet Earnings Analysis: Q4 Recap

The earnings results for Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) for Q4 were made public on Monday, November 25, 2024 at 04:02 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Central Garden & Pet Q4 Earnings Assessment

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.02 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Central Garden & Pet Q4

WIIM

CENT

Central Garden & Pet shares are trading lower after the company reported Q4 sales that missed analyst estimates, despite better-than-expected adjusted EPS.

Guidance

Central Garden & Pet Company Sees FY25 Non-GAAP EPS $2.20 Or Better vs $2.44 Est.

Earnings Beats

Earnings Misses

Central Garden & Pet Q4 2024 Adj. EPS $(0.18) Beats $(0.20) Estimate, Sales $669M Miss $706.184M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly loss at $0.10 per share on revenue of $4.12 million. 
• Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) is estimated to report earnings for its second quarter. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $227.49 million. 
• Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $68.00 million. 
• Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $1.58 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.16 per share on revenue of $5.95 million. 
<h3>Companies Reporting After The Bell</h3>
• BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $776.51 million. 
• Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $1.67 billion. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $706.77 million. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $707.30 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its third quarter. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly loss at $0.02 per share on revenue of $69.82 million. 
• Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $404.09 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $232.90 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $40.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.31 billion. 
• Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $1.16 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is likely to report quarterly earnings at $1.25 per share on revenue of $812.95 million. 
• Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) is expected to report quarterly earnings at $0.67 per share on revenue of $324.70 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $199.08 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $407.00 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $36.14 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $48.95 million. 
• Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is likely to report quarterly loss at $1.16 per share on revenue of $17.93 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

BBWI

BLBD

BLRX

CRGO

ENTA

FLNC

HSAI

LESL

PFLT

PNNT

SMTC

SUPV

TBBB

UXIN

Earnings Scheduled For November 25, 2024

JP Morgan analyst Andrea Faria Teixeira maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $34 to $32.

JP Morgan Maintains Neutral on Central Garden & Pet, Lowers Price Target to $32

In late 2023, many analysts called for 2024 to be the year of a small-cap stock renaissance. These stocks were battered as the Federal Reserve aggressively raised interest rates. Many of these companies rely on borrowing to fund their growth and struggled as the cost of borrowing increased.&nbsp;
The Russell 2000 index, which tracks many small-cap stocks, is up 20% in 2024. But not all small-cap stocks participated in that rally. However, with the Federal Reserve suggesting that its 50-basis point cut in September was the first in a series of future rate cuts, borrowing conditions should improve for small-cap stocks, particularly those that already show solid fundamentals like the stocks mentioned here. &nbsp;
Analysts are projecting earnings growth of at least 10% in the next 12 months for each of these companies. That growth and other catalysts make these stocks strong candidates to outperform the market in the next 12 months. &nbsp;
<h2>Star Bulk Carriers Will Benefit From China&#39;s Stimulus Measures&nbsp;</h2>
Dry bulk carrier stocks aren&#39;t the most exciting. But Star Bulk Carriers Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sblk#NASDAQ">SBLK</a>) is one to watch heading into 2025. It&#39;s the largest U.S.-listed dry bulk company with a fleet of 160 vessels. The company also has a strong balance sheet and has been paying down debt at a rate of about $250 million per year, a pace it expects to continue to match in the future.
However, a key reason for the company&#39;s short-term growth will likely come from China. The company has noted that dry bulk shipments to China were up about 7.5% in the first seven months of 2024. That was before the company announced new stimulus measures, which will likely increase demand for imports of raw materials like iron ore.&nbsp;&nbsp;
Then, you have to consider the company&#39;s valuation. SBLK stock is trading at just 6.9x forward earnings. The stock is up 7.6% in 2024, but analysts have a consensus price target of $29.33 which gives investors about 28% upside to go along with a dividend that has a 12.2% yield. The one risk is higher oil prices which would hurt earnings. &nbsp;
<h2>Evolv Technologies Is a Play on the Application of AI&nbsp;</h2>
Unfortunately, the nation experienced another school shooting in September. Perhaps anecdotally, the share price of Evolv Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlv#NASDAQ">EVLV</a>) is up 59% in the 90 days ending October 3, 2024. Evolv provides a next-generation metal detection system that is rooted in artificial intelligence (AI).
A key benefit of the company&#39;s Evolv Express system is that it provides a truly touchless security screening system. This allows an uninterrupted traffic flow into and out of the venues in which it operates. In fact, the company&#39;s technology has screened over one billion people since 2019. &nbsp;
The company&#39;s products are used by one or more teams in every professional sports league. Evolv&#39;s customer base also includes hospitals, churches, and school systems that are looking for a non-invasive way to screen for firearms, explosives, and tactical knives. &nbsp;
However, even with the sharp move higher in the last three months, EVLV stock is still down 17.3% for the year and over 15% in the last 12 months. One concern is earnings. The company just posted its first profitable quarter. Another concern is competition. However, the company&#39;s annual recurring revenue (ARR) continues to rise, suggesting this concern may be overstated. &nbsp;
<h2>Central Garden &amp; Pet Company May Be an Undiscovered Gem&nbsp;</h2>
Last on this list of small-cap stocks poised for growth in 2025 is Central Garden &amp; Pet Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/centa#NASDAQ">CENTA</a>). As its name suggests, the company&#39;s business is divided into two verticals. Its garden sector offers a range of lawn and garden supplies, while its Pet sector provides supplies for dogs, cats, and other pets.
Like many consumer discretionary stocks, CENTA stock lags the broader market. However, it&#39;s still up about 3.8% in 2024. This comes as the company is showing a slight decline in the top line, which is offset by earnings that are growing year-over-year.&nbsp;
However, the company points to its customer base which continues to spend on their pets. The company has also taken steps in its garden division to navigate through external challenges that are a constant in the business. &nbsp;
The CENTA analyst forecasts on MarketBeat show bullish sentiment for the stock. The $42 consensus price target gives the stock an upside of 43%. &nbsp;
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-small-cap-stocks-on-the-way-to-bigger-and-better-days/">3 Small-Cap Stocks on the Way to Bigger and Better Days</a>&quot; first appeared on MarketBeat.

Niko Lahanas, Former Central CFO, Brings 18 Years of Experience at the Company
Brad Smith, Former CFO, Pet Segment, Appointed Central CFO
Interim CEO and Director Beth Springer to Return to Role of Lead Independent Director
Central Garden &amp; Pet Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>), ("Central" or "the Company"), a market leader in the Pet and Garden industries, announced today that <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fniko-lahanas%2F&amp;esheet=54127962&amp;newsitemid=20240927935178&amp;lan=en-US&amp;anchor=Niko+Lahanas&amp;index=1&amp;md5=c5360414556d7108604d77cecea22146">Niko Lahanas</a> has been appointed Chief Executive Officer, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fbradleygsmith8%2F&amp;esheet=54127962&amp;newsitemid=20240927935178&amp;lan=en-US&amp;anchor=Brad+Smith&amp;index=2&amp;md5=ea7f3ee9d4b415755d8ba616d59cc1b7">Brad Smith</a> has been appointed Chief Financial Officer, effective September 29, 2024. Mr. Lahanas will also join Central's Board of Directors. Mr. Lahanas succeeds Beth Springer, who has served as Interim Chief Executive Officer since October, 2023. Ms. Springer will return to the role of Lead Independent Director.

Management

Central Garden & Pet Appoints Niko Lahanas As CEO And Brad Smith As CFO; Interim CEO And Director Beth Springer To Return To Role Of Lead Independent Director

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our<a href="https://www.benzinga.com/analyst-stock-ratings"> analyst ratings page.</a>
<ul>
<li>Canaccord Genuity cut the price target for Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) from $23 to $18. Canaccord Genuity analyst Michael Graham maintained a Buy rating. Lyft shares fell 17.2% to close at $9.08 on Wednesday. <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush slashed the price target for Dine Brands Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) from $37 to $34. Wedbush analyst Nick Setyan maintained the stock with a Neutral rating. Dine Brands Global shares fell 4.6% to close at $30.44 on Wednesday. <a href="https://www.benzinga.com/quote/DIN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) price target from $144 to $147. Piper Sandler analyst Peter Keith maintained an Overweight rating. Boot Barn shares fell 1.6% to close at $115.70 on Wednesday. <a href="https://www.benzinga.com/quote/BOOT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for Central Garden &amp; Pet Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) from $38 to $34. JP Morgan analyst Andrea Faria Teixeira maintained a Neutral rating. Central Garden shares fell 1.1% to close at $32.70 on Wednesday. <a href="https://www.benzinga.com/quote/CENTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) price target from $12 to $6. Morgan Stanley analyst Nathan Feather maintained an Equal-Weight rating. Bumble shares rose 1.9% to close at $8.06 on Wednesday. <a href="https://www.benzinga.com/quote/BMBL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted Editas Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) price target from $13 to $15. B of A Securities analyst Greg Harrison upgraded the stock from Neutral to Buy. Editas Medicine shares fell 12.2% to close at $4.11 on Wednesday. <a href="https://www.benzinga.com/quote/EDIT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised the price target for PetIQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETQ#NASDAQ">PETQ</a>) from $30 to $31. Truist Securities analyst Bill Chappell downgraded the stock from Buy to Hold. PetIQ shares gained 47.9% to close at $30.42 on Wednesday. <a href="https://www.benzinga.com/quote/PETQ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $145 to $110. Needham analyst Laura Martin maintained a Buy rating. Disney shares fell 4.5% to close at $85.96 on Wednesday. <a href="https://www.benzinga.com/quote/DIS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird slashed Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) price target from $239 to $191. Baird analyst Eric Coldwell downgraded the stock from Outperform to Neutral. Charles River Laboratories shares fell 12.6% to close at $199.96 on Wednesday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $694 to $671. Baird analyst Eric Coldwell maintained an Outperform rating. McKesson shares gained 0.5% to close at $617.51 on Wednesday. <a href="https://www.benzinga.com/analyst-stock-ratings">See how other analysts view this stock.</a></li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40243140/us-stocks-decline-as-smcis-margin-miss-brings-nvidia-and-other-ai-stocks-under-pressure-investor-se">US Stocks Decline As SMCI&#8217;s Margin Miss Brings Nvidia And Other AI Stocks Under Pressure: Investor Sentiment Remains In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

JP Morgan analyst Andrea Faria Teixeira maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $38 to $34.

JP Morgan Maintains Neutral on Central Garden & Pet, Lowers Price Target to $34

Central Garden & Pet Sees FY24 Adj. EPS $2.00 Or Better Vs $2.19 Est.

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.20 by 10 percent. The company reported quarterly sales of $996.348 million which missed the analyst consensus estimate of $1.002 billion by 0.52 percent. This is a 2.61 percent decrease over sales of $1.023 billion the same period last year.

Central Garden & Pet Q3 2024 Adj. EPS $1.32 Beats $1.20 Estimate, Sales $996.348M Miss $1.002B Estimate

JP Morgan analyst Andrea Faria Teixeira maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $40 to $38.

JP Morgan Maintains Neutral on Central Garden & Pet, Lowers Price Target to $38

Truist Securities analyst Bill Chappell maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Buy and raises the price target from $45 to $50.

Truist Securities Maintains Buy on Central Garden & Pet, Raises Price Target to $50

Fiscal 2024 Guidance
Central continues to expect fiscal 2024 non-GAAP EPS to be $2.00 or better ($2.50 or better before the February 2024 stock dividend).
This outlook reflects uncertain consumer demand and retailer dynamics and an environment of macroeconomic and geopolitical volatility. It includes modest carryover pricing actions to help mitigate inflationary headwinds. This outlook excludes the impact of any acquisitions, divestitures or restructuring activities that may occur during fiscal 2024, including any projects under the Cost and Simplicity program and the recent TDBBS acquisition. Central expects fiscal 2024 capital spending to be approximately $70 million.

Central Garden & Pet Continues To Expect FY24 Non-GAAP EPS To Be $2.00 Or Better ($2.50 Or Better Before The February 2024 Stock Dividend) Vs $2.23 Est

Warning: CENTA is at high risk of performing badly

Central Garden & Pet Company: Generating Consistent And Sustainable FCF Across Different Economic Cycles

Truist Financial analyst Bill Chappell maintained a Buy rating on Central Garden Pet (CENT – Research Report) on October 17 and set a price target ...

Truist Financial Reaffirms Their Buy Rating on Central Garden Pet (CENT)

Central Garden & Pet Company 2024 Q4 - Results - Earnings Call Presentation

Central Garden & Pet Company (CENT) Q4 2024 Earnings Call Transcript

Analyst Brian McNamara from Canaccord Genuity maintained a Buy rating on Central Garden Pet (CENT – Research Report) and decreased the price target...

Central Garden & Pet: Overcoming Q4 Misses with Strategic Growth Initiatives and Optimism for Future Recovery

In a report released today, Bill Chappell from Truist Financial maintained a Buy rating on Central Garden Pet (CENT – Research Report). The company...

Truist Financial Remains a Buy on Central Garden Pet (CENT)

Central Garden Pet (CENT – Research Report) received a Hold rating and price target from Argus Research analyst Christine Dooley yesterday. The com...

Argus Research downgrades Central Garden Pet (CENT) to a Hold

Oil-Dri Corporation of America: Not Ready For A Change Just Yet

In a report released on January 16, Andrea Faria Teixeira from J.P. Morgan maintained a Hold rating on Central Garden Pet (CENT – Research Report),...

Comments

Central Garden & Pet

News

Latest news for Central Garden & Pet (NASDAQ:CENTA) Stock

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga